Sell Alert: 5 Stocks Analysts Downgraded on Wednesday
Analysts downgraded five stocks on Wednesday, November 11, 2026. Halozyme (HALO) was downgraded by Morgan Stanley to Equal-Weight with a $109 price target. Life360 (LIF) was downgraded by BofA Securities to Neutral with a $45 price target. Akamai (AKAM) was downgraded by Evercore ISI to In-Line with a $90 price target. Riot Platforms (RIOT) was downgraded by Keefe, Bruyette & Woods to Market Perform with a $23 price target.
How this was made

The 30-second read
Why it matters
Downgrades and target cuts provide fresh sell‑side catalysts for the listed companies, potentially driving short‑term price declines.
Market read
Analyst rating changes are immediate triggers for trading decisions in the affected stocks.
What to watch
Potential upside from upcoming product pipelines or contract wins not reflected in the downgrades.
Background
The article compiles a list of five stocks that received analyst downgrades on Wednesday, November 11, 2026.
Ticker impact
Analyst Morgan Stanley downgraded Halozyme Therapeutics and lowered its price target on November 11.
likely pressure as the market prices in the downgrade
Analyst downgrade is a fresh catalyst that typically triggers sell‑offs for small‑cap biotech.
BofA Securities cut Life360 to Neutral and reduced its price target on November 11.
likely pressure as investors digest the lower outlook
Downgrade with a 33% target reduction is a material new piece of information.
Evercore ISI downgraded Akamai Technologies and cut its price target on November 11.
likely pressure as the market reacts to the downgrade
Analyst downgrade is a fresh catalyst for a technology stock.
Keefe, Bruyette & Woods moved Riot Platforms to Market Perform and raised its price target on November 11.
limited move, possible slight upside from rating upgrade
Rating upgrade may offset target increase; impact expected to be muted.
Market effects
Technology and biotech sectors may see broader sell‑offs as analysts tighten expectations.
U.S. small‑cap and growth stocks could face heightened volatility.
Limited to U.S. equities; no direct global macro effect.
Counterpoint
Some investors may view the downgrades as over‑reaction and look for buying opportunities.
Key entities
- AnalystMorgan Stanley
Downgraded Halozyme Therapeutics.
- AnalystBofA Securities
Downgraded Life360.
- AnalystEvercore ISI
Downgraded Akamai Technologies.
- AnalystKeefe, Bruyette & Woods
Moved Riot Platforms to Market Perform.

